Physician profile
Timothy Morrow
NPI 1558331868
$1,599.00
in general payments reported to CMS, 2019-2025
27 companies · $34.76 in 2025
The $34.76 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $177 · 2021: $420 · 2022: $424 · 2023: $255 · 2024: $61.70 · 2025: $34.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209.93 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $142.62 | 2019-2023 | Xiaflex, Aveed, Edex |
| Pfizer INC. | $115.04 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $109.16 | 2021-2022 | |
| Janssen Biotech, INC. | $101.64 | 2021-2022 | |
| Astellas Pharma US INC | $100.98 | 2019-2023 | Myrbetriq |
| Accord Healthcare, INC. | $99.28 | 2022 | |
| Healthtronics Stone Solutions, LLC | $83.48 | 2021 | |
| Antares Pharma, INC. | $81.28 | 2022-2025 | Xyosted |
| Angiodynamics, INC. | $74.27 | 2022 | |
| Myovant Sciences INC. | $74.08 | 2021-2022 | |
| Mission Pharmacal Company | $47.98 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $45.68 | 2019-2023 | Provenge |
| Rochester Medical Corporation | $44.16 | 2021 | |
| Coloplast Corp | $33.45 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $28.59 | 2020-2021 | |
| Innovation Technologies INC | $23.83 | 2023 | Irrisept |
| Ethicon US, LLC | $22.32 | 2023 | Stratafix |
| Hollister Incorporated | $21.27 | 2023 | Vapro |
| Therapeuticsmd, INC. | $21.10 | 2019 | |
| Verity Pharmaceuticals INC. | $20.89 | 2024 | Trelstar |
| Boston Scientific Corporation | $20.37 | 2023 | |
| Sumitomo Pharma America, INC. | $19.94 | 2023 | Orgovyx |
| Endo USA, INC. | $19.89 | 2024 | Xiaflex |
| Medtronic USA, INC. | $16.76 | 2020 | |
| Blue Earth Diagnostics | $15.26 | 2022 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.